
A study evaluated the efficacy and safety of low-dose spironolactone in treating IgA nephropathy (IgAN) patients. Among 88 patients, 24-hour proteinuria decreased significantly from 0.93 g to 0.70 g after two months of spironolactone treatment, with a slight reduction in estimated glomerular filtration rate (eGFR) from 75.7 to 73.9 mL/min/1.73 m². Patients with effective treatment showed reduced endocapillary hypercellularity, while those with ineffective treatment saw increased proteinuria initially, which later decreased with continued treatment. Spironolactone further reduced proteinuria from 0.95 g to 0.50 g by six months in patients with persistent high proteinuria during prednisone therapy. The treatment was safe, with no instances of hyperkalemia.
Like
Save
Share